The notices it replaced
- Reissues: PAR-19-231 NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)
Replaced by PAR-25-358.
Who won it before
10 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $3,107,808 in first-year total cost, median $266,421.
Most frequent study sections
- Special Emphasis Panel[ZEY1 VSN (01)]10
Most frequent institutions
- OHIO STATE UNIVERSITY3
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO3
- JOHNS HOPKINS UNIVERSITY1
- LEGACY EMANUEL HOSPITAL AND HEALTH CENTER1
- STANFORD UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Decentralized Dry Eye Study, Planning & Feasibility1R34EY037743-01 | SEITZMAN, GERAMI D | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $492,000 | ZEY1 |
| 2024 | Designing a Pragmatic Registry-based Randomized Controlled Trial for Open-Angle Glaucoma Treatment in the US1R34EY036161-01 | SUN, CATHERINE QING | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $491,429 | ZEY1 |
| 2024 | Identification of School-age Eye conditions Evaluation (ISEE)1R34EY035783-01 | CINER, ELISE BCOLLINS, MEGAN EKULP, MARJEAN TYING, GUI-SHUANG | OHIO STATE UNIVERSITY, OH | $267,006 | ZEY1 |
| 2024 | Feasibility Studies for the Future Mediterranean Glucose Lowering Dietfor Vision Extension in AMD (M-GLOVE-AMD)1R34EY035782-01 | HARTNETT, MARY ELIZABETH RUTH | STANFORD UNIVERSITY, CA | $265,835 | ZEY1 |
| 2023 | Planning the VICTORY (VIsual ComplicaTions Of PrematuRitY) Study1R34EY034969-01 | DAMMANN, OLAF | TUFTS UNIVERSITY BOSTON, MA | $313,034 | ZEY1 |
| 2022 | Feasibility of study to delay myopia onset1R34EY033395-01A1 · under PAR-19-231 | BERNTSEN, DAVID AWALLINE, JEFFREY JAY | OHIO STATE UNIVERSITY, OH | $249,797 | ZEY1 |
| 2021 | 80 Years and Older Vision & Hearing Important Persons Project (80VIP)1R34EY031427-01A1 · under PAR-19-231 | MANSBERGER, STEVEN L | LEGACY EMANUEL HOSPITAL AND HEALTH CENTER, OR | $252,345 | ZEY1 |
| 2020 | Vision disorders in adolescents following concussion1R34EY030582-01A1 · under PAR-19-231 | JORDAN, LISA AROBERTS, TAWNA | OHIO STATE UNIVERSITY, OH | $294,281 | ZEY1 |
| 2020 | Planning study for a phase-2 randomized multi-center placebo-controlled treatment trial of retinitis pigmentosa1R34EY031429-01 · under PAR-19-231 | CAMPOCHIARO, PETER AKONG, XIANGRONG | JOHNS HOPKINS UNIVERSITY, MD | $245,625 | ZEY1 |
| 2020 | Oral metformin for non-neovascular age-related macular degeneration1R34EY031719-01 · under PAR-19-231 | STEWART, JAY MICHAEL | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $236,456 | ZEY1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.